Ionis Income Tax Expense vs Ebit Analysis

IONS Stock

USD 35.90 0.53 1.50%

Ionis Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ionis Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ionis Pharmaceuticals is a good investment. Please check the relationship between Ionis Pharmaceuticals Income Tax Expense and its Ebit accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Income Tax Expense vs Ebit

Income Tax Expense vs Ebit Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ionis Pharmaceuticals Income Tax Expense account and Ebit. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Ionis Pharmaceuticals' Income Tax Expense and Ebit is -0.11. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Ebit in the same time period over historical financial statements of Ionis Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ionis Pharmaceuticals' Income Tax Expense and Ebit is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Ionis Pharmaceuticals are associated (or correlated) with its Ebit. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebit has no effect on the direction of Income Tax Expense i.e., Ionis Pharmaceuticals' Income Tax Expense and Ebit go up and down completely randomly.

Correlation Coefficient

-0.11

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Income Tax Expense

Ebit

Most indicators from Ionis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 33.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.16 in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	829M	984M	1.1B	1.2B
Cost Of Revenue	11M	14M	9.1M	8.7M

Total Operating Expenses Cost Of Revenue

Ionis Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Net Receivables	Property Plant And Equipment Gross	Short Term Investments	Common Stock	Other Assets
Total Assets		0.87	0.58	0.92	0.73	0.86	-0.16	-0.6	0.68	0.94	0.6	1.0	0.59	0.93	0.96	0.94	0.93	1.0	0.3	0.74	0.52	0.5	0.83	0.96	0.43	0.64
Short Long Term Debt Total	0.87		0.72	0.93	0.34	0.96	0.21	-0.8	0.41	0.69	0.17	0.87	0.49	0.98	0.92	0.84	0.98	0.89	0.23	0.74	0.51	0.59	0.97	0.84	0.4	0.32
Other Current Liab	0.58	0.72		0.65	0.11	0.64	0.36	-0.53	0.11	0.54	0.2	0.57	0.22	0.69	0.55	0.51	0.69	0.58	-0.46	0.41	0.42	0.35	0.7	0.56	0.23	0.22
Total Current Liabilities	0.92	0.93	0.65		0.43	0.93	0.18	-0.8	0.4	0.79	0.33	0.91	0.5	0.97	0.93	0.9	0.98	0.93	0.34	0.72	0.67	0.61	0.91	0.91	0.43	0.33
Total Stockholder Equity	0.73	0.34	0.11	0.43		0.38	-0.75	-0.04	0.9	0.83	0.87	0.73	0.59	0.43	0.61	0.66	0.43	0.7	0.24	0.5	0.18	0.09	0.26	0.67	0.32	0.86
Property Plant And Equipment Net	0.86	0.96	0.64	0.93	0.38		0.17	-0.84	0.43	0.72	0.18	0.86	0.57	0.94	0.91	0.89	0.94	0.88	0.32	0.81	0.5	0.49	0.94	0.85	0.52	0.25
Net Debt	-0.16	0.21	0.36	0.18	-0.75	0.17		-0.38	-0.8	-0.31	-0.62	-0.17	-0.4	0.17	-0.05	-0.16	0.17	-0.14	-0.09	-0.11	0.09	0.3	0.33	-0.1	-0.13	-0.64
Retained Earnings	-0.6	-0.8	-0.53	-0.8	-0.04	-0.84	-0.38		-0.12	-0.42	0.12	-0.6	-0.62	-0.78	-0.64	-0.76	-0.78	-0.62	-0.27	-0.8	-0.7	-0.47	-0.81	-0.54	-0.71	0.07
Cash	0.68	0.41	0.11	0.4	0.9	0.43	-0.8	-0.12		0.72	0.69	0.69	0.66	0.44	0.61	0.66	0.43	0.67	0.23	0.53	0.23	0.09	0.28	0.61	0.35	0.79
Non Current Assets Total	0.94	0.69	0.54	0.79	0.83	0.72	-0.31	-0.42	0.72		0.81	0.93	0.57	0.78	0.83	0.87	0.78	0.92	0.16	0.66	0.48	0.31	0.64	0.91	0.42	0.72
Non Currrent Assets Other	0.6	0.17	0.2	0.33	0.87	0.18	-0.62	0.12	0.69	0.81		0.59	0.36	0.3	0.41	0.48	0.3	0.56	-0.03	0.26	0.25	0.02	0.1	0.57	0.16	0.83
Cash And Short Term Investments	1.0	0.87	0.57	0.91	0.73	0.86	-0.17	-0.6	0.69	0.93	0.59		0.6	0.93	0.96	0.94	0.93	1.0	0.3	0.74	0.52	0.49	0.83	0.95	0.43	0.65
Common Stock Shares Outstanding	0.59	0.49	0.22	0.5	0.59	0.57	-0.4	-0.62	0.66	0.57	0.36	0.6		0.49	0.51	0.77	0.49	0.59	0.2	0.88	0.53	0.13	0.42	0.46	0.86	0.38
Non Current Liabilities Total	0.93	0.98	0.69	0.97	0.43	0.94	0.17	-0.78	0.44	0.78	0.3	0.93	0.49		0.95	0.88	1.0	0.94	0.28	0.73	0.56	0.61	0.96	0.89	0.39	0.4
Other Current Assets	0.96	0.92	0.55	0.93	0.61	0.91	-0.05	-0.64	0.61	0.83	0.41	0.96	0.51	0.95		0.9	0.95	0.97	0.4	0.72	0.44	0.57	0.89	0.95	0.34	0.53
Other Stockholder Equity	0.94	0.84	0.51	0.9	0.66	0.89	-0.16	-0.76	0.66	0.87	0.48	0.94	0.77	0.88	0.9		0.89	0.94	0.35	0.88	0.64	0.45	0.8	0.87	0.69	0.51
Total Liab	0.93	0.98	0.69	0.98	0.43	0.94	0.17	-0.78	0.43	0.78	0.3	0.93	0.49	1.0	0.95	0.89		0.94	0.29	0.73	0.58	0.61	0.96	0.9	0.4	0.39
Total Current Assets	1.0	0.89	0.58	0.93	0.7	0.88	-0.14	-0.62	0.67	0.92	0.56	1.0	0.59	0.94	0.97	0.94	0.94		0.32	0.75	0.52	0.53	0.85	0.95	0.42	0.62
Short Term Debt	0.3	0.23	-0.46	0.34	0.24	0.32	-0.09	-0.27	0.23	0.16	-0.03	0.3	0.2	0.28	0.4	0.35	0.29	0.32		0.29	0.1	0.33	0.24	0.33	0.11	-0.01
Intangible Assets	0.74	0.74	0.41	0.72	0.5	0.81	-0.11	-0.8	0.53	0.66	0.26	0.74	0.88	0.73	0.72	0.88	0.73	0.75	0.29		0.52	0.29	0.72	0.64	0.81	0.34
Accounts Payable	0.52	0.51	0.42	0.67	0.18	0.5	0.09	-0.7	0.23	0.48	0.25	0.52	0.53	0.56	0.44	0.64	0.58	0.52	0.1	0.52		0.33	0.43	0.47	0.56	0.1
Net Receivables	0.5	0.59	0.35	0.61	0.09	0.49	0.3	-0.47	0.09	0.31	0.02	0.49	0.13	0.61	0.57	0.45	0.61	0.53	0.33	0.29	0.33		0.57	0.48	0.04	0.1
Property Plant And Equipment Gross	0.83	0.97	0.7	0.91	0.26	0.94	0.33	-0.81	0.28	0.64	0.1	0.83	0.42	0.96	0.89	0.8	0.96	0.85	0.24	0.72	0.43	0.57		0.81	0.39	0.28
Short Term Investments	0.96	0.84	0.56	0.91	0.67	0.85	-0.1	-0.54	0.61	0.91	0.57	0.95	0.46	0.89	0.95	0.87	0.9	0.95	0.33	0.64	0.47	0.48	0.81		0.29	0.57
Common Stock	0.43	0.4	0.23	0.43	0.32	0.52	-0.13	-0.71	0.35	0.42	0.16	0.43	0.86	0.39	0.34	0.69	0.4	0.42	0.11	0.81	0.56	0.04	0.39	0.29		0.15
Other Assets	0.64	0.32	0.22	0.33	0.86	0.25	-0.64	0.07	0.79	0.72	0.83	0.65	0.38	0.4	0.53	0.51	0.39	0.62	-0.01	0.34	0.1	0.1	0.28	0.57	0.15

Click cells to compare fundamentals

Ionis Pharmaceuticals Account Relationship Matchups

Ionis Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.2B	2.4B	2.6B	2.5B	3.0B	3.1B
Short Long Term Debt Total	772.0M	808.9M	1.2B	1.3B	1.5B	1.5B
Other Current Liab	136.9M	(128.4M)	127.6M	189.3M	215.6M	226.4M
Total Current Liabilities	273M	290M	241M	312M	448.1M	470.5M
Total Stockholder Equity	1.5B	843M	772M	573M	386.7M	265.7M
Property Plant And Equipment Net	154M	181M	178M	256M	242.9M	255.1M
Net Debt	(1.8B)	(1.1B)	(954M)	(642M)	1.1B	1.1B
Retained Earnings	(707.5M)	(1.2B)	(1.2B)	(1.4B)	(1.8B)	(1.7B)
Cash	2.5B	1.9B	2.1B	2.0B	399.3M	534.5M
Non Current Assets Total	512M	260M	267M	331M	348.2M	365.6M
Non Currrent Assets Other	358M	51.1M	60.0M	34.6M	62.3M	34.5M
Cash And Short Term Investments	2.5B	1.9B	2.1B	2.0B	2.3B	2.4B
Common Stock Shares Outstanding	142.9M	139.6M	141.0M	141.8M	143.2M	83.9M
Liabilities And Stockholders Equity	3.2B	2.4B	2.6B	2.5B	3.0B	3.1B
Non Current Liabilities Total	1.3B	1.3B	1.6B	1.6B	2.2B	2.3B
Other Current Assets	158M	162M	168M	157.7M	184.4M	193.7M
Other Stockholder Equity	2.2B	2.1B	2.0B	2.1B	2.2B	2.3B
Total Liab	1.5B	1.5B	1.8B	2.0B	2.6B	2.7B
Total Current Assets	2.7B	2.1B	2.3B	2.2B	2.6B	2.8B
Short Term Debt	2.0M	293.2M	3.5M	7.5M	53.2M	55.8M
Intangible Assets	24.0M	25.7M	27.9M	29.0M	33.4M	24.2M
Accounts Payable	16.1M	17.2M	11.9M	17.9M	26.0M	27.3M
Net Receivables	63M	76M	62M	25.5M	97.8M	102.7M
Property Plant And Equipment Gross	153.7M	181.1M	280.7M	256M	339.7M	356.7M
Accumulated Other Comprehensive Income	(25.3M)	(21.1M)	(32.7M)	(57.5M)	(32.6M)	(31.0M)
Short Term Investments	1.8B	1.5B	1.2B	1.7B	1.9B	2.0B
Other Assets	310.6M	78.0M	319M	35.0M	40.2M	57.3M
Long Term Debt	770.0M	515.7M	1.2B	1.2B	1.2B	1.3B
Property Plant Equipment	153.7M	181.1M	178.1M	74.3M	85.4M	79.6M
Other Liab	490.1M	424M	352M	287.8M	330.9M	170.0M
Current Deferred Revenue	118M	108M	98M	91M	151.1M	158.7M
Inventory	18.2M	22.0M	24.8M	22.0M	28.4M	29.8M
Net Tangible Assets	1.4B	815.4M	742.7M	572.9M	658.8M	531.9M
Retained Earnings Total Equity	(707.5M)	(1.2B)	(1.2B)	(1.4B)	(1.3B)	(1.4B)
Long Term Debt Total	770.0M	515.7M	1.2B	1.2B	1.4B	1.4B
Capital Surpluse	2.2B	2.1B	2.0B	2.1B	2.4B	1.7B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC